News
European Commission approves Pfizer’s atopic dermatitis treatment
The approval from the European Commission (EC) is based on the results of five clinical studies, involving over 2,800 patients.
You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.
The approval from the European Commission (EC) is based on the results of five clinical studies, involving over 2,800 patients.